ProGear ASTM Level 3 Masks with Oxafence Active Protection (Box of 50 Masks)
ProGear ASTM Level 3 Masks with Oxafence Active Protection (Box of 50 Masks)
ProGear ASTM Level 3 Masks with Oxafence Active Protection (Box of 50 Masks)
ProGear ASTM Level 3 Masks with Oxafence Active Protection (Box of 50 Masks)
ProGear ASTM Level 3 Masks with Oxafence Active Protection (Box of 50 Masks)
1/5

ProGear ASTM Level 3 Masks with Oxafence Active Protection (Box of 50 Masks)

$38.10
$38.10
Save $-38.10 Sold out

The newest ProGear ASTM Level 3 Surgical Masks now contain Oxafence Active Protection technology. Oxafence inactivates 99.9% of tested viruses* after 5 minutes, including H1N1 Influenza and OC43 Coronavirus Isolates* (see full IFU for more information).

You get the quality, function, and comfort that ProGear is known for, including:

  • Particulate Filtration, Bacterial Filtration, and Fluid Resistance performance that meet or exceed ASTM Level 3 Standards (F2100-23)
  • Patented Wave-Fit® Pre-bent Nosepiece
  • Oxafence Active Protection, which kills tested viruses* on masks while they are being worn.
  • Made in USA.

Bulk (by the case) purchases can be made at ProGearHealth.com. Pricing: $238.10/case (10 boxes/case = 500 masks).
  • Flat $10 shipping on each order.

Indications for Use: The ProGear Surgical Mask with Oxafence is a single-use, disposable device used to cover the nose and mouth of the wearer to protect from transfer of microorganisms, body fluids and particulates. The outer layer of the face mask is coated with methylene blue (0.47 micrograms per square cm area).

*The ProGear Surgical Mask with Oxafence inactivates single isolates of the following test viruses after five minutes of contact with the treated surface of the face mask in laboratory (in vitro) tests under a lighting intensity of 500 ± 25 lux: Influenza A/PR/8/34/H1N1 (TC adapted, ATCC VR-1469), 3 log or 99.9% inactivation; Betacoronavirus 1 OC43 (ATCC VR-1558), 4 log or 99.99% inactivation; Feline Calicivirus F-9 (ATCC VR- 782), 4 log or 99.99% inactivation. Antiviral efficacy on other viruses has not been evaluated. Correlations between in vitro testing results and any clinical event have not been evaluated.